NASDAQ · Medical - Devices

Standard BioTools Inc. (LAB) Stock

$0.69 +2.85% NASDAQ: LAB Healthcare

Valuation

MetricValue
Price$0.69
Market Cap$269.87M
P/E Ratio-3.23
P/B Ratio0.54
P/S Ratio3.45
EPS (TTM)$-0.20
52-Week High$1.72
52-Week Low$0.63
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-18.16%
ROA-13.93%
ROCE-14.06%
Gross Margin-110.59%
Operating Margin-109.41%
Net Margin-103.29%
Debt/Equity0.05
Current Ratio4.20

Annual Financials (USD)

Metric20212022202320242025
Revenue$131.0M$98.0M$106.0M$174.0M$85.0M
Operating Profit$-67.0M$-116.0M$-77.0M$-175.0M$-93.0M
Net Profit$-59.0M$-190.0M$-75.0M$-139.0M$-75.0M
EPS$-0.78$-2.43$-0.94$-0.52$-0.20
Op Margin-51.7%-118.6%-72.0%-100.5%-109.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$275.0M$390.0M$323.0M$612.0M$568.0M
Total Liabilities$181.0M$472.0M$471.0M$141.0M$143.0M
Cash$28.0M$81.0M$52.0M$167.0M$118.0M
Borrowings$112.0M$103.0M$98.0M$33.0M$31.0M

Latest News

Stealthy startup Treeline plans a reverse merger BioPharma Dive · Jun 9, 2026 Standard BioTools, Treeline Biosciences to Merge in All-Stock Deal MT Newswires · Jun 8, 2026 Standard BioTools and Treeline Biosciences Announce Merger Agreement GlobeNewswire · Jun 8, 2026 Standard BioTools Regains Compliance With Nasdaq's Minimum Bid Price Requirement MT Newswires · Jun 8, 2026 Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates Zacks · May 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-44.0M$-89.0M$-43.0M$-143.0M$-74.0M
Investing Cash Flow$-25.0M$-92.0M$17.0M$355.0M$16.0M
Financing Cash Flow$6.0M$213.0M$-5.0M$-39.0M$0
Net Cash Flow$-40.0M$53.0M$-30.0M$116.0M$-48.0M
Free Cash Flow$-57.0M$-93.0M$-46.0M$-152.0M$-83.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.45
EV / EBITDA-0.54
FCF Yield-28.33%
Quick Ratio8.80
Interest Coverage-5346.33
Return 1Y-39.63%
Return 3Y-63.07%
Return 5Y-85.19%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADCTADC Therapeutics SA $1.73 +8.81% -2.14 $220.04M 0.00%
AVNS $24.99 +0.04% 19.96 $1.17B 0.00%
BVSBioventus Inc. $13.07 +2.96% 16.85 $885.13M 0.00%
CBLLCeriBell, Inc. $23.63 +2.07% -13.46 $896.59M 0.00%
CGEMCullinan Therapeutics, Inc. $15.53 +0.45% -4.60 $954.44M 0.00%

About Standard BioTools Inc.

Standard BioTools Inc. is led by CEO Michael Egholm, publicly traded since 2011.

Standard BioTools Inc. (LAB) stock trades at $0.69 with a market capitalization of $269.87M. The stock is valued at a price-to-earnings (P/E) ratio of -3.23, price-to-book of 0.54, price-to-sales of 3.45. Over the past 52 weeks the stock has ranged between $0.63 and $1.72, and currently trades 59.9% below its 52-week high.

On profitability, Standard BioTools Inc. generates a return on equity (ROE) of -18.16%, return on capital employed of -14.06%, an operating margin of -109.41%, a net profit margin of -103.29%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides